TCGA-B6-A0I5-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 285
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_LATE+0.410
- ESTROGEN_RESPONSE_EARLY+0.360
- MYC_TARGETS_V2+0.310
- COAGULATION+0.290
- APICAL_SURFACE+0.270
- PANCREAS_BETA_CELLS+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- KRAS_SIGNALING_DN+0.260
- MYOGENESIS+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.210
Top 10 suppressed
- MITOTIC_SPINDLE-0.520
- PROTEIN_SECRETION-0.470
- G2M_CHECKPOINT-0.440
- E2F_TARGETS-0.420
- INTERFERON_ALPHA_RESPONSE-0.410
- TGF_BETA_SIGNALING-0.390
- UV_RESPONSE_DN-0.360
- INTERFERON_GAMMA_RESPONSE-0.310
- PI3K_AKT_MTOR_SIGNALING-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A3TM-01A-11R-A22K-07 | — | B | 0.831 |
| 2 | TCGA-V7-A7HQ-01A-11R-A33J-07 | — | B | 0.826 |
| 3 | MBCProject_0988_T1_RNA | — | B | 0.819 |
| 4 | TCGA-AO-A0JB-01A-11R-A32Y-07 | — | B | 0.818 |
| 5 | MNG1265 | — | — | 0.815 |
| 6 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.810 |
| 7 | MNG1103 | — | — | 0.808 |
| 8 | TCGA-LD-A66U-01A-11R-A31O-07 | — | B | 0.795 |
| 9 | TCGA-AC-A3QP-01A-11R-A22U-07 | — | B | 0.794 |
| 10 | TCGA-AN-A0FT-01A-11R-A034-07 | — | B | 0.791 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_LATE | 0.410 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |